AU2002252891A1 - Oligonucleotide compositions and their use to induce differentiation of cells - Google Patents
Oligonucleotide compositions and their use to induce differentiation of cellsInfo
- Publication number
- AU2002252891A1 AU2002252891A1 AU2002252891A AU2002252891A AU2002252891A1 AU 2002252891 A1 AU2002252891 A1 AU 2002252891A1 AU 2002252891 A AU2002252891 A AU 2002252891A AU 2002252891 A AU2002252891 A AU 2002252891A AU 2002252891 A1 AU2002252891 A1 AU 2002252891A1
- Authority
- AU
- Australia
- Prior art keywords
- cells
- seq
- differentiation
- human
- leukemia
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Description
OLIGONUC EOTIDE COMPOSITIONS AND THEIR USE TO INDUCE
DIFFERENTIATION OF CELLS
FIELD OF THE INVENTION
The present invention provides compositions comprising specific oligonucleotides combined with a pharmaceutically acceptable carrier, wherein the compositions are useful to induce differentiation of cells, including pluripotent cells, leukemic cells, lymphoma cells and bone marrow-derived cells, and to treat diseases such as leukemia, lymphoma and disorders associated with insufficient differentiation of cells.
BACKGROUND OF THE INVENTION
Numerous diseases and conditions in animals and humans are associated with insufficient differentiation of cells or with an insufficiency of cells. Many of these cells are derived from bone marrow. Such diseases and conditions include but are not limited to leukemia, lymphoma, and non-malignant blood disorders such as hemoglobinopathies, sickle cell disease, myelodysplastic syndrome and insufficient production of bone marrow derived cells following therapies such as radiation and chemotherapy.
Differentiation therapy of leukemia cells in diseases such as acute promyelocytic leukemia (APL), acute myeloid leukemia (AML), chronic promyelocytic leukemia (CPL) and chronic myeloid leukemia (CML), has provided an alternative strategy for the treatment of leukemia. In differentiation therapy, immature leukemia cells are induced by different chemical compounds to attain a mature phenotype resulting in arrest of their growth. A number of differentiation compounds and also radiation have been reported to induce the differentiation of leukemia cells. Hemin, butyric acid, 5-azacytidine, cytosine arabinoside, hydroxyurea, guanosine, guanine, retinoic acid, trimidox, gamma-irradiation, mithramycin and chromomycin have been reported to induce differentiation of leukemia cells (Rutherford et al., Nature 280:164, 1979; Gambari et al., Biochem. Biophys. Acta, 886:203, 1986; Bianchi et al., Cancer Res. 46:6327, 1986; Adunyah et al., Biochem. Biophys. Acta, 1263:123, 1995; Osti et al., Haematologica 82:395, 1997; Cortesi et al., Eur. J. Haematol. 61:295, 1998; lyamu et al., Biochem. Biophys. Res. Com. 247:759,
1998; Schwenke et al., Leulc. Res. 19:955, 1995; and Bianchi et al, Br. J. Haematol. 104:258, 1999).
Synthetic oligonucleotides are polyanionic sequences that are internalized in cells (Nlassov et al. Biochim. Biophys. Acta 1197:95, 1994). Synthetic oligonucleotides are reported to bind selectively to nucleic acids (Wagner, R. Nature: 372:333, 1994), to specific cellular proteins (Bates et al. J. Biol. Chem. 274:26369, 1999) and to specific nuclear proteins (Scaggiante et al. Eur. J. Biochem. 252:207, 1998), and to inhibit proliferation of cancer cells. Synthetic oligonucleotides have not been reported to possess differentiating activity on acute and/or chronic pro-myelocytic cells and/or myeloid leukemia cells. Synthetic phosphorothioate oligonucleotides having a CpG motif (S'purme-purme-cytosine (C) -guanine (G) -pyrimidine-pyrimidine3') have been shown to induce the proliferation of B-cell chronic lymphocytic leukemia (Decker et al., Blood 95:999, 2000). Synthetic 27 base sequences containing G and variable amounts of thymine (T), hereinafter oligonucleotide GTn, wherein n is > 1 or < 7 Ts (Scaggiante et al., Eur. J. Biochem. 252:207, 1998), and wherein the number of bases is >20 (Morassutti et al., Nucleosides and Nucleotides 18:1711, 1999), have been reported to inhibit growth of leukemia cells by sequence specific binding to a 45 kDa nuclear protein. In contrast, GTn sequences, wherein the total number of bases is less than 15, are reported to be inactive against these cells (Morassutti et al. Nucleosides and Nucleotides 18:1711, 1999). Chimeric methylphosphonodiester/phosphodiester oligonucleotides of sequence type CGNNN (N = A, C, G or T), introduced into the cytoplasm of cells by 10 minutes of reversible permeabilization with streptolysin O, induce apoptosis of human T cell leukemia cells. Nevertheless, the CGNNN oligonucleotides are reported to be inactive against three CML cell lines (K562, LAMA84 and KYO1), showing no significant effect on the growth and survival of these cells (Tidd et al., Nucleic Acid Res. 28:2242, 2000).
Depletion of bone marrow derived cells is observed in several conditions, including depletion following radiation therapy or chemotherapy. Insufficient production of cells destined to become erythrocytes or granulocytes is associated with numerous problems, including but not limited to, reduced delivery of oxygen to cells, decreased immune function, and clotting abnormalities. Narious therapies, including expensive chemotherapies, are often required to stimulate production of red and white cells.
Most prior art differentiating therapies have proven to be less than adequate for clinical applications. Many of these therapies are inefficient or toxic, have significant adverse effects and are debilitating for the recipient. Therefore, there is a continuing need for novel compositions and methods that induce differentiation of cells such as myeloid- derived leukemia cells. What is also needed are new therapeutic compositions and methods that stimulate production and differentiation of pluripotent cells such as bone- marrow derived cells. Also needed are new therapeutic compositions that induce differentiation of cells. What is also needed are compositions and methods that may be used to treat diseases and conditions characterized by insufficient differentiation of cells or insufficient production of marrow derived cells.
SUMMARY OF THE INVENTION
The present invention fulfills these needs by providing a method comprising administration of a composition comprising a 3'-OH, 5'-OH, chemically unmodified, synthetic phosphodiester oligonucleotide sequence (hereinafter sequence) selected from the group consisting of SEQ ID NO: 1 (5*GTG3*), SEQ ID NO: 2 (5'GGGTGG3')5 SEQ ID NO: 3 (5'GGGAGG3') and SEQ ID NO: 4 (5'CCACCC3') and a pharmaceutically acceptable carrier, wherein the composition induces differentiation of cells. The present invention provides a method to treat diseases associated with growth of cells that are not differentiated to a mature phenotype. Terminal differentiation of cells may include one or more responses selected from the group consisting of induction of erythrocyte-like phenotype, monocyte-like phenotype, megakaryocyte-like phenotype, inhibition of proliferation of leukemia cells and induction of hemoglobin synthesis.
The compositions of the present invention may be used to treat diseases related to insufficient differentiation of cells. Such diseases include but are not limited to leukemia, lymphoma, and non-malignant blood disorders such as hemoglobinopathies, sickle cell disease or myelodysplastic syndrome. The compositions of the present invention are believed to be useful for treatment of pancytopenia, anemia, thrombocytopenia and leukopenia. Other conditions that may be treated with the compositions of the present invention include lymphoma and nonmalignant blood disorders, including but not limited to hemoglobinopathies, sickle cell disease and myelodysplastic syndromes. In a preferred
embodiment, the compositions of the present invention are administered to an animal or a human with leukemia in an amount effective to treat the leukemia.
The compositions of the present invention may also be administered to an animal or human together with other therapies as a combination therapy . These therapies may include administration of therapeutic compounds or radiation therapy. The compositions of the present invention may be administered before, after, or concomitantly with the other therapy. Such combination therapy may augment the net therapeutic effect on the animal or human. The compositions of the present invention may be administered alone, or in combination with other therapeutic modalities including, but not limited to, chemotherapeutic agents, differentiating agents, immunotherapeutic agents, antimicrobial agents, antiviral agents or in combination with radiation therapy.
The compositions of the present invention may be administered to a recipient to stimulate production of cells after other therapies administered to the recipient have depleted such cells. One non-limiting example involves depletion of cells derived from bone marrow following radiation therapy or chemotherapy. The compositions of the present invention may also be administered to a recipient to stimulate production and differentiation of other cells such as pluripotent stem cells, myeloid stem cells, lymphoid stem cells, progenitor cells, immune cell precursors, and/or other cells derived from these pluripotent stem cells, myeloid stem cells, lymphoid stem cells, progenitor cells, and immune cell precursors. The compositions of the present invention may also be administered to a recipient to stimulate production and differentiation of cells from numerous sources, including but not limited to, bone marrow, liver, spleen, lymph nodes, thymus and cord blood.
The compositions of the present invention may also be administered in vitro to affect differentiation of cells such as pluripotent stem cells, myeloid stem cells, lymphoid stem cells, progenitor cells, immune cell precursors, and/or other cells derived from these pluripotent stem cells, myeloid stem cells, lymphoid stem cells, progenitor cells, and immune cell precursors.
The unexpected and surprising ability of the composition of the present invention to induce differentiation of bone-marrow derived cells, including leukemia cells, addresses a long-felt, unfulfilled need in the medical arts and provides an important benefit for animals and humans.
Accordingly, it is an object of the present invention to provide a method comprising administration of a composition comprising a 3'-OH, 5'-OH, chemically unmodified, synthetic phosphodiester oligonucleotide sequence (hereinafter sequence) selected from the group consisting of SEQ ID NO: 1 (5'GTG3'), SEQ ID NO: 2 (5'GGGTGG3')3 SEQ ID NO: 3 (5'GGGAGG3') and SEQ ID NO: 4 (5'CCACCC3') and a pharmaceutically acceptable carrier to treat disease in animals and humans, wherein the disease is characterized by insufficient differentiation of cells.
Another object of the present invention is to provide a method comprising administration of a composition comprising a 3'-OH, 5'-OH, chemically unmodified, synthetic phosphodiester oligonucleotide sequence (hereinafter sequence) selected from the group consisting of SEQ ID NO: 1 (5'GTG3'), SEQ ID NO: 2 (5'GGGTGG3*), SEQ ID NO: 3 (5*GGGAGG3') and SEQ ID NO: 4 (5'CCACCC3') and a pharmaceutically acceptable carrier to induce progenitor cell maturation and differentiation in animals and humans. Another object of the present invention is to provide a composition and method to treat leukemia.
Yet another object of the present invention is to provide a method that inhibits proliferation of leukemic cells and induces differentiation of leukemic cells.
Another object of the present invention is to provide a method to treat lymphoma. Yet another object of the present invention is to provide a method to treat non- malignant blood disorders.
Still another object of the present invention is to provide a method to treat hemoglobinopathies.
A further object of the present invention is to provide a method to treat sickle cell disease.
Yet another object of the present invention is to provide a method to treat myelodysplastic syndrome.
Another object of the present invention is to provide a method to treat pancytopenia. Yet another object of the present invention is to provide a method to treat anemia.
A further object of the present invention is to provide a method to treat thrombocytopenia.
Another object of the present invention is to provide a method to treat leukopenia.
Still another object of the present invention is to provide a method to induce progenitor cell maturation and differentiation.
Yet another object of the present invention is to provide a method to induce maturation and differentiation of cells including but not limited to pluripotent stem cells, myeloid stem cells, lymphoid stem cells, progenitor cells, immune cell precursors, and/or other cells derived from these pluripotent stem cells, myeloid stem cells, lymphoid stem cells, progenitor cells, and immune cell precursors.
Still another object of the present invention is to provide a method to induce bone marrow-derived progenitor cell maturation.
Another object of the present invention is to provide a method that increases the number of bone marrow derived-cells following treatment with therapeutic agents.
Yet another object of the present invention is to provide a method that increases the number of bone marrow derived-cells following treatment with chemotherapeutic agents.
Another object of the present invention is to provide a method that restores the number of bone marrow derived-cells following treatment with radiotherapy.
Still another object of the present invention is to provide a method that restores the number of bone marrow derived-cells following treatment with immunosuppressive agents.
Still another object of the present invention is to provide a composition that is minimally toxic to the recipient.
These and other objects, features and advantages of the present invention will become apparent after a review of the following detailed description of the disclosed embodiments and the appended claims.
DETAILED DESCRIPTION OF THE INVENTION
The present invention may be understood more readily by reference to the following detailed description of specific embodiments included herein. The present invention comprises a method comprising administration of a composition comprising a 3'-OH, 5'-OH, chemically unmodified, synthetic phosphodiester oligonucleotide sequences (hereinafter sequence) selected from the group consisting of
SEQ ID NOs: 1, 2, 3, or 4, and a pharmaceutically acceptable carrier, to an animal or a human in an amount effective to induce differentiation of cells. The compositions of the present invention may be used to treat disease related to insufficient differentiation of cells. Such diseases include but are not limited to leukemia, lymphoma, and non- malignant blood disorders such as hemoglobinopathies, sickle cell disease and myelodysplastic syndrome. The compositions of the present invention are believed to be useful for treatment of pancytopenia, anemia, thrombocytopenia and leukopenia. Other conditions that may be treated with the compositions of the present invention include lymphoma and nonmalignant blood disorders, including but not limited to hemoglobinopathies, sickle cell disease and myelodysplastic syndromes. The unexpected and surprising ability of these compositions to induce differentiation and to inhibit proliferation of leukemia cells addresses a long felt unfulfilled need in the medical arts and provides an important benefit for animals and humans.
The present invention also comprises a method comprising administration of a composition comprising a 3'-OH, 5 -OH, chemically unmodified, synthetic phosphodiester oligonucleotide sequence (hereinafter sequence) selected from the group consisting of SEQ ID NO: 1 (5'GTG3'), SEQ ID NO: 2 (5'GGGTGG3'), SEQ ID NO: 3 (5'GGGAGG3') and SEQ ID NO: 4 (5'CCACCC3?) and a pharmaceutically acceptable carrier, to induce maturation of progenitor cells in animals and humans. Such cells include but are not limited to pluripotent stem cells, myeloid stem cells, lymphoid stem cells, immune cell precursors, and/or other cells derived from these pluripotent stem cells, myeloid stem cells, lymphoid stem cells and immune cell precursors. The compositions of the present invention may also be administered to an animal or human to stimulate production and differentiation of cells from numerous sources, including but not limited to, bone marrow, liver, spleen, lymph nodes, thymus and cord blood.
As used herein, the word "sequence" refers a sequence comprising a 3'-OH, 5'-OH chemically unmodified, synthetic phosphodiester nucleotide sequence selected from the group consisting of SEQ ID NO: 1 (5'GTG3'), SEQ ID NO: 2 (5'GGGTGG3')5 SEQ ID NO: 3 (5'GGGAGG3') and SEQ ID NO: 4 (5'CCACCC3'). The word "response", as used herein refers to one or more of the following non- limiting examples of responses: induced differentiation of pluripotent stem cells, myeloid stem cells, lymphoid stem cells, immune cell precursors, and/or other cells derived from
these pluripotent stem cells, myeloid stem cells, lymphoid stem cells and immune cell precursors; induced differentiation of erythrocyte-like cells, monocyte-like cells or megakaryocyte-like cells; inhibition of cellular proliferation due to the induction of terminal differentiation; induction of hemoglobin synthesis; and stimulation of hemoglobin synthesis.
As used herein, the phrase "effective in responsive cells" refers to the ability of the compositions of the present invention to induce differentiation and/or inhibition of proliferation and/or synthesis of hemoglobin.
As used herein, the phrases "therapeutic treatment", "effective amount" and "amount effective to" refer to an amount of a sequence effective to induce differentiation of cells, to inhibit proliferation of cells or to stimulate production of pluripotent cells such as bone marrow-derived cells.
The word "disease", as used herein, relates to a condition wherein bodily health is impaired. As used herein, the phrase "chemotherapeutic" is any agent approved by a regulatory agency of a country or a state government or listed in the U.S. Pharmacopoeia or other generally recognized pharmacopoeia for use to treat cancer in an animal or human. As used herein, the phrase "chemotherapeutic" includes immunosuppressive agents. Administration of an effective amount of the composition of the present invention to an animal or a human is a therapeutic treatment that prevents, treats or eliminates a disease including, but not limited to, leukemia, pancytopenia, anemia, thrombocytopenia, leukopenia, lymphoma, and non-malignant blood disorders such as hemoglobinopathies, sickle cell disease or myelodysplastic syndrome. Types of leukemia include, but are not limited to APL, AML, CPL and CML. Administration of an effective amount of the composition of the present invention to an animal or a human is also a therapeutic treatment that stimulates production of progenitor cells, including but not limited to pluripotent stem cells, myeloid stem cells, lymphoid stem cells, immune cell precursors, and/or other cells derived from these pluripotent stem cells, myeloid stem cells, lymphoid stem cells and immune cell precursors, hi a preferred embodiment, the present invention provides a method to stimulate production and differentiation of marrow derived cells. The compositions of the present invention may also be administered to an animal or
human to stimulate production and differentiation of cells from numerous sources, including but not limited to, bone marrow, liver, spleen, lymph nodes, thymus and cord blood.
The terms "pharmaceutically acceptable carrier" or "pharmaceutically acceptable vehicle" are used herein to mean, without limitation, any liquid, solid or semi-solid, including, but not limited to, water or saline, a gel, cream, salve, solvent, diluent, fluid ointment base, ointment, paste, implant, liposome, micelle, giant micelle, and the like, which is suitable for use in contact with living animal or human tissue without causing adverse physiological responses, and which does not interact with the other components of the composition in a deleterious manner. Other pharmaceutically acceptable carriers or vehicles known to one of skill in the art may be employed to make compositions for delivering the oligonucleotide sequences of the present invention.
The oligonucleotide sequences of the present invention may be combined with pharmaceutically acceptable carriers and administered as compositions in vitro or in vivo. Forms of administration include, but are not limited to, injections, solutions, creams, gels, implants, pumps, ointments, emulsions, suspensions, microspheres, particles, microparticles, nanoparticles, liposomes, pastes, patches, tablets, transdermal delivery devices, sprays, aerosols, or other means familiar to one of ordinary skill in the art. Such pharmaceutically acceptable carriers are commonly known to one of ordinary skill in the art. Pharmaceutical formulations of the present invention can be prepared by procedures known in the art using well known and readily available ingredients. For example, the compounds can be formulated with common excipients, diluents, or carriers, and formed into tablets, capsules, suspensions, powders, and the like. Examples of excipients, diluents, and carriers that are suitable for such formulations include the following: fillers and extenders (e.g., starch, sugars, mannitol, and silicic derivatives); binding agents (e.g., carboxymethyl cellulose and other cellulose derivatives, alginates, gelatin, and polyvinyl- pyrrolidone); moisturizing agents (e.g., glycerol); disintegrating agents (e.g., calcium carbonate and sodium bicarbonate); agents for retarding dissolution (e.g., paraffin); resorption accelerators (e.g., quaternary ammonium compounds); surface active agents (e.g., cetyl alcohol, glycerol monostearate); adsorptive carriers (e.g., kaolin and bentonite); emulsifiers; preservatives; sweeteners; stabilizers; coloring agents; perfuming agents;
flavoring agents; lubricants (e.g., talc, calcium and magnesium stearate); solid polyethyl glycols; and mixtures thereof.
The formulations can be so constituted that they release the active ingredient only or preferably in a particular location, possibly over a period of time. Such combinations provide yet a further mechanism for controlling release kinetics. The coatings, envelopes, and protective matrices may be made, for example, from polymeric substances or waxes.
Compositions comprising one or more sequences and a pharmaceutically acceptable carrier are prepared by uniformly and intimately bringing into association the sequence and the pharmaceutically acceptable carrier. Phannaceutically acceptable carriers include liquid carriers, solid carriers or both. Liquid carriers are aqueous carriers, non-aqueous carriers or both, and include, but are not limited to, aqueous suspensions, oil emulsions, water-in-oil emulsions, water-in-oil-in-water emulsions, site-specific emulsions, long-residence emulsions, sticky-emulsions, microemulsions and nanoemulsions. Solid carriers are biological carriers, chemical carriers or both and include, but are not limited to, viral vector systems, particles, microparticles, nanoparticles, microspheres, nanospheres, minipumps, bacterial cell wall extracts and biodegradable or non-biodegradable natural or synthetic polymers that allow for sustained release of the oligonucleotide compositions. Emulsions, minipumps and polymers can be implanted in the vicinity of where delivery is required (Brem et al. J. Neurosurg. 74: 441, 1991). Methods used to complex an oligonucleotide sequence(s) to a solid carrier include, but are not limited to, direct adsorption to the surface of the solid carrier, covalent coupling to the surface of the solid carrier, either directly or via a linking moiety, and covalent coupling to the polymer used to make the solid carrier. Optionally, a sequence(s) can be stabilized by the addition of non-ionic or ionic polymers such as polyoxyethylenesorbitan monooleates (TWEENs) or hyaluronic acid.
Preferred aqueous carriers include, but are not limited to, water, saline and pharmaceutically acceptable buffers. Preferred non-aqueous carriers include, but are not limited to, a mineral oil or a neutral oil including, but not limited to, a diglyceride, a triglyceride, a phospholipid, a lipid, an oil and mixtures thereof, wherein the oil contains an appropriate mix of polyunsaturated and saturated fatty acids. Examples include, but are not limited to, soybean oil, canola oil, palm oil, olive oil and myglyol, wherein the fatty acids can be saturated or unsaturated. Optionally, excipients may be included regardless of
the pharmaceutically acceptable canier used to present the oligonucleotide compositions to cells. These excipients include, but are not limited to, anti-oxidants, buffers, and bacteriostats, and may include suspending agents and thickening agents.
One or more sequences may be administered alone, or in combination with other therapeutic modalities including, but not limited to, chemotherapeutic agents, differentiating agents, immunotherapeutic agents, antimicrobial agents, antiviral agents or in combination with radiation therapy. Differentiating agents include, but are not limited to, hemin, butyric acid, 5-azacytidine, cytosine arabinoside, hydroxyurea, guanosine, guanine, retinoic acid, trimidox, gamma-irradiation, mithramycin and chromomycin. Chemotherapeutic agents include, but are not limited to, anti-metabolites, DNA damaging, microtubule destabilizing, microtubule stabilizing, actin depolymerizing, growth inhibiting, topoisomerase inhibiting, HMG-CoA inhibiting, purine inhibiting, pyrimidine inhibiting, metalloproteinase inhibiting, CDK inhibiting, angiogenesis inhibiting, differentiation enhancing and immunotherapeutic agents. Dosages and methods of administration of these other therapeutic modalities are known to one of ordinary skill in the art.
Methods of in vivo administration of the compositions of the present invention, or of formulations comprising such compositions and other materials such as earners of the present invention that are particularly suitable for various forms include, but are not limited to the following types of administration, oral (e.g. buccal or sublingual), anal, rectal, as a suppository, topical, parenteral, aerosol, inhalation, intrathecal, intraperitoneal, intravenous, intraarterial, transdermal, intradermal, subdennal, intramuscular, intrauterine, vaginal, into a body cavity, surgical administration at the location of a tumor or internal injury, directly into tumors, into the lumen or parenchyma of an organ, and into bone marrow. Techniques useful in the various forms of administrations mentioned above include but are not limited to, topical application, ingestion, surgical admimsfration, injections, sprays, transdermal delivery devices, osmotic pumps, electrodepositing directly on a desired site, or other means familiar to one of ordinary skill in the art. Sites of application can be external, such as on the epidermis, or internal, for example a gastric ulcer, a surgical field, or elsewhere.
The compositions of the present invention can be applied in the form of creams, gels, solutions, suspensions, liposomes, particles, or other means known to one of skill in
the art of formulation and delivery of the compositions. Ultrafine particle sizes can be used for inhalation delivery of therapeutics. Some examples of appropriate formulations for subcutaneous administration include but are not limited to implants, depot, needles, capsules, and osmotic pumps. Some examples of appropriate formulations for vaginal administration include but are not limited to creams and rings. Some examples of appropriate formulations for oral administration include but are not limited to: pills, liquids, syrups, and suspensions. Some examples of appropriate formulations for transdermal administration include but are not limited to gels, creams, pastes, patches, sprays, and gels. Some examples of appropriate delivery mechanisms for subcutaneous administration include but are not limited to implants, depots, needles, capsules, and osmotic pumps. Formulations suitable for parenteral administration include but are not limited to aqueous and non-aqueous sterile injection solutions which may contain anti- oxidants, buffers, bacteriostats and solutes which render the formulation isotonic with the blood of the intended recipient, and aqueous and non-aqueous sterile suspensions which may include suspending agents and thickening agents. Extemporaneous injection solutions and suspensions may be prepared from sterile powders, granules and tablets commonly used by one of ordinary skill in the art.
Embodiments in which the compositions of the invention are combined with, for example, one or more pharmaceutically acceptable carriers or excipients may conveniently be presented in unit dosage form and may be prepared by conventional pharmaceutical techniques. Such techniques include the step of bringing into association the compositions containing the active ingredient and the pharmaceutical carrier(s) or excipient(s). In general, the formulations are prepared by uniformly and intimately bringing into association the active ingredient with liquid carriers. Prefened unit dosage formulations are those containing a dose or unit, or an appropriate fraction thereof, of the administered ingredient. It should be understood that in addition to the ingredients particularly mentioned above, formulations comprising the compositions of the present invention may include other agents commonly used by one of ordinary skill in the art.
The volume of administration will vary depending on the route of administration. Such volumes are known to one of ordinary skill in the art of administering compositions to animals or humans. Depending on the route of administration, the volume per dose is preferably about 0.001 to 100 ml per dose, more preferably about 0.01 to 50 ml per dose
and most preferably about 0.1 to 30 ml per dose. For example, intramuscular injections may range in volume from about 0.1 ml to 1.0 ml. The oligonucleotide compositions administered alone, or together with other therapeutic agent(s), can be administered in a single dose treatment, in multiple dose treatments, or continuously infused on a schedule and over a period of time appropriate to the disease being treated, the condition of the recipient and the route of administration. Moreover, the other therapeutic agent can be administered before, at the same time as, or after administration of the oligonucleotide compositions.
Preferably, the amount of oligonucleotide composition administered per dose is from about 0.0001 to 100 mg/kg, more preferably from about 0.001 to 10 mg/kg and most preferably from about 0.01 to 5 mg/kg. In a preferred embodiment, the oligonucleotide compositions in combination with a chemotherapeutic agent is administered to an animal or human having leukemia in an amount effective to add to, synergize with or potentiate the anti-neoplastic effect of the chemotherapeutic agent. Preferably, the amount of therapeutic agent administered per dose is from about 0.001 to 1000 mg/kg, more preferably from about 0.01 to 500 mg/kg and most preferably from about 0.1 to 100 mg/kg. The particular sequence and the particular therapeutic agent administered, the amount per dose, the dose schedule and the route of administration should be decided by the practitioner using methods known to those skilled in the art and will depend on the type of disease, the severity of the disease, the location of the disease and other clinical factors such as the size, weight and physical condition of the recipient. In addition, in vitro assays may optionally be employed to help identify optimal ranges for sequence and for sequence plus therapeutic agent administration.
The compositions of the present invention may also be administered in vitro to affect differentiation of cells such as pluripotent stem cells, myeloid stem cells, lymphoid stem cells, progenitor cells, immune cell precursors, and/or other cells derived from these pluripotent stem cells, myeloid stem cells, lymphoid stem cells, progenitor cells, and immune cell precursors.
The present invention is further illustrated by the following examples, which are not to be construed in any way as imposing limitations upon the scope thereof. On the contrary, it is to be clearly understood that resort may be had to various other embodiments, modifications, and equivalents thereof, which, after reading the description
herein, may suggest themselves to those skilled in the art without departing from the spirit of the present invention.
Example 1 Preparation of sequences
Phosphodiester nucleotide sequences (SEQ ID NOs: 1, 2, 3 and 4) were prepared by Sigma-Genosys (Woodlands, TX) using Abacus Segmented Synthesis Technology.
Unless stated otherwise, the sequences were dispersed in autoclaved deionized water or in a pharmaceutically acceptable buffer such as, but not limited to, saline immediately prior to use.
Example 2 Cells
The K562 cell line derived from the leukemic cells of a CML patient in blastic crisis is used as the standard model for determining, in vitro, the therapeutic potential of new differentiating compounds (Rutherford et al., Nature, 280:164, 1979; Drexler et al. DSMZ Catalogue of Human and Animal Cell Lines, 6th ed., Braunschweig, Germany: DSMZ, 1997). K562 cells were obtained from the American Type Culture Collection (ATCC, Rockville, MD) and were cultured in the medium recommended by the ATCC.
Example 3 Hemoglobin synthesis by K562 cells cultured with SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3 and SEQ ID NO: 4.
K562 cells were seeded in 1.0 ml at 2.0 X 10*5 cells/ml in 6-well flat-bottomed tissue culture plates for 72 hours with 100 μg of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3 or SEQ ID NO: 4. For hemoglobin determination, the cells were washed twice by centrifugation in phosphate-buffered saline (PBS), stained with 0.2% benzidine (Sigma- Aldrich Canada, Oakville, Ontario) in 0.5 M acetic acid activated with 10% H2O2 (Gambari et al., Experimentia 41:673, 1985). After 10 minutes incubation in the dark, the percentages of benzidine positive cells (hemoglobin positive cells) were determined by light microscopy using an hemocytometer. Approximately 500 cells were counted for the determination of the percentages of benzidine positive cells. Cell size was also determined
by light microscopy. Hemin (20 μg) was added to K562 cells for 72 hours as a control for hemoglobin synthesis. Hemin was obtained from Sigma-Aldrich Canada.
Table 1 Evaluation of hemoglobin synthesis (benzidine-positivity) and cell size of K562 cells
As shown in Table 1, SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3 and SEQ ID NO: 4 induce the synthesis of hemoglobin by K562 cells and an increase in their cell size, two measures of erythroid differentiation.
Example 4 Upregulation ofRh D in K562 cells cultured with SEQ ID NO: 2 or SEQ ID NO: 3.
The Rh D antigen is the most important antigen of the Rh blood group system. In humans, the Rh D antigen is expressed solely on erythrocytes (Cartron, Blood Rev. 6:199,
1994). K562 cells were seeded in 1.0 ml at 2.0 X 105 cells/ml in 6-well flat-bottomed tissue culture plates for 72 hours with 2.5, 10.0, 25.0, 50.0 or 100.0 μg of SEQ ID NO: 2 or SEQ ID NO: 3. The expression of Rh D at the cell surface was monitored by flow cytometry. After incubation, K562 cells were washed twice by centrifugation with PBS and labeled with phycoerythrin (PE)-conjugated anti-Rh D monoclonal antibody (IBGRL research product, Bristol, Netherlands) for 30 min at 4°C. After washing twice with PBS- 1% bovine serum albumin, cellular fluorescence was then determined. Flow cytometry was carried out on a FACSCalibur cell sorter (Becton Dickinson, San Jose, CA, USA) and analyzed using the program CELLQuest (Becton Dickinson). The fold increase in Rh D level over control (0 μg oligonucleotide) was determined. Untreated K562 cells were essentially negative for this marker.
Table 2 Fold increase in Rh D level over control in treated K562 with SEQ ID NO: 2 and SEQ ID NO: 3
As shown in Table 2, SEQ ID NO: 2 and SEQ ID NO: 3 induced the expression of Rh D antigen at the cell surface of K562, a measure of erythroid differentiation.
Example 5 Upregulation of CD41a antigen in K562 cells cultured with SEQ ID NO: 2 or SEQ ID NO: 3.
The CD41a antigen, also named Gpllb/Iila, is expressed on platelets and megakaryocytes (Gruel et al., Blood 68:488, 1986). K562 cells were seeded in 1.0 ml at
2.0 X 10*5 cells/ml in 6-well flat-bottomed tissue culture plates for 72 hours with 2.5, 10.0, 25.0, 50.0 or 100.0 μg of SEQ ID NO: 2 or SEQ ID NO: 3. The expression of CD41a at the cell surface was monitored by flow cytometry. After incubation, K562 cells were washed twice by centrifugation with PBS and labeled with phycoerythrin (PE)-conjugated anti-CD41a monoclonal antibody (BD Pharmingen, Mississauga, Ontario, Canada) for 30 min at 4°C. After washing twice with PBS-1% bovine serum albumin, cellular fluorescence was then determined. Flow cytometry was carried out on a FACSCalibur cell sorter (Becton Dickinson) and analyzed using the program CELLQuest (Becton Dickinson). The fold increase in CD41a level over control (0 μg oligonucleotide) was determined. Untreated K562 cells were essentially negative for this marker.
Table 3 Fold increase in CD41a level over control in treated K562 cells with SEQ ID NO: 2 or SEQ ID NO: 3
As shown in Table 3, SEQ ID NO: 2 and SEQ ID NO: 3 induced the expression of CD41a antigen, a measure of megakaryocyte differentiation, at the cell surface of K562 cells.
Example 6 Upregulation of CD 14 in K562 cells cultured with SEQ ID NO: 2 or SEQ ID NO: 3. The CD14 antigen is expressed at high levels on monocytes. Additionally, CD14 is expressed on interfollicular macrophages, reticular dendritic cells and some Langherans cells (Wright et al., Science 249:1434, 1990). K562 cells were seeded in 1.0 ml at 2.0 X
10*5 cells/ml in 6-well flat-bottomed tissue culture plates for 72 hours with 2.5, 10.0, 25.0, 50.0 or 100.0 μg of SEQ ID NO: 2 or SEQ ID NO: 3. The expression of CD14 at the cell surface was monitored by flow cytometry. After incubation, K562 cells were washed twice by centrifugation with PBS and labeled with fluorescein isothiocyanate (FITC)- conjugated anti-CD14 monoclonal antibody (BD Pharmingen) for 30 min at 4°C. After washing twice with PBS-1% bovine serum albumin, cellular fluorescence was then determined. Flow cytometry was carried out on a FACSCalibur cell sorter (Becton Dickinson) and analyzed using the program CELLQuest (Becton Dickinson). The fold increase in CD14 level over control (0 μg oligonucleotide) was determined. Untreated K562 cells were essentially negative for this marker.
Table 4 Fold increase in CD14 level over control in K562 cells treated with SEQ ID NO: 2 or SEQ ID NO: 3
As shown in Table 4, SEQ ID NO: 2 and SEQ ID NO: 3 induced the expression of CD14 antigen, a measure of monocyte differentiation, at the cell surface of K562 cells.
Example 7 Induction ofCD14+Rh D+, CD14+CD41a+ andRh D+CD41a+ phenotype in K562 cells cultured with SEQ ID NO: 2.
K562 cells were seeded in 1.0 ml at 2.0 X 10-5 cells/ml in 6-well flat-bottomed tissue culture plates for 72 hours with 2.5, 10.0, 25.0, 50.0 or 100.0 μg of SEQ ID NO: 2. The expression of CD 14, CD41a and Rh D at the cell surface was monitored by two dimensional flow cytometry. After incubation, K562 cells were washed twice by centrifugation with PBS and labeled with FITC-conjugated anti-CD14, PE-conjugated anti-CD41a and/or PE-conjugated anti-Rh D monoclonal antibody (BD Pharmingen) for 30 min at 4°C. After washing twice with PBS-1% bovine serum albumin, cellular fluorescence was determined. Flow cytometry was carried out on a FACSCalibur cell sorter (Becton Dickinson) and analyzed using the program CELLQuest (Becton Dickinson). The fold increase in 0)14*101 D+, CD14+CD41a+ and Rh D+CD41a+ level over control (0 μg oligonucleotide) was determined. Untreated K562 cells were essentially negative for these markers.
Table 5 Fold increase in CD14+Rh D+, CD14+CD41a+ and Rh D+CD41a+ levels in K562 treated with SEQ ID NO: 2
PHENOTYPE Concentration (μg/ml)
2.5 10 25 50 100
CD14"T h D+ 4.0 x 7.0 x 16.0 x 34.0 x 41.0 x
CD14+CD41a+ 2.0 x 2.0 x 4.0 x ll.O x 22.0 x
Rh D+CD41a+ 20.0 x 22.0 x 45. Ox 87.0 x 100.7 x
As shown in Table 5, SEQ ID NO: 2 induced the differentiation of K562 cells into cells with heterogeneous phenotypes.
Example 8 Induction ofCD14+Rh D+, CD14+CD41a+ andRh D+CD41a+ phenotype in K562 cells cultured with SEQ ID NO: 3.
K562 cells were seeded in 1.0 ml at 2.0 X \ cells/ml in 6-well flat-bottomed tissue culture plates for 72 hours with 2.5, 10.0, 25.0, 50.0 or 100.0 μg of SEQ ID NO: 3. The expression of CD 14, CD41a and Rh D at the cell surface was monitored by two dimensional flow cytometry. After incubation, K562 cells were washed twice by centrifugation with PBS and labeled with FITC-conjugated anti-CD 14, PE-conjugated anti-CD41a and/or PE-conjugated anti-Rh D monoclonal antibody (BD Pharmingen) for 30 min at 4°C. After washing twice with PBS-1% bovine serum albumin, cellular fluorescence was then determined. Flow cytometry was carried out on a FACSCalibur cell sorter (Becton Dickinson) and analyzed using the program CELLQuest (Becton Dickinson). The fold increase in CDM !^ D+, CD14+CD41a+ and Rh D+CD41a+ level over control (0 μg oligonucleotide) was determined. Untreated K562 cells were essentially negative for these markers.
Table 6 Fold increase in CD14+Rh D+, CD14+CD41a+ and Rl D+CD41a+ levels in K562 treated with SEQ ID NO: 3
PHENOTYPE Concentration (μg/ml)
2.5 10 25 50 100
CD14+Rh D+ 7.0 x 8.0 x 9.0 x l l.O x 10.0 x
CD14+CD41a+ 2.0 x 3.0 x 4.0 x 4.0 x 3.0 x
Rh D+CD41a+ 6.0 x 4.0 x 7.0x 29.0 x 31.0 x
As shown in Table 6, SEQ ID NO: 3 induced the differentiation of K562 cells into cells with heterogeneous phenotypes.
Example 9 Inhibition ofK562 cell growth by SEQ ID NO: 2 and SEQ ID NO: 3.
Terminal differentiation of K562 cells has been reported to stop their cellular growth (Bianchi et al, Biochem. Pharmacol. 60:31, 2000). K562 cells were seeded in 1.0 ml at 2.0 X 10**** cells/ml in 6-well flat-bottomed tissue culture plates for 72 hours with 1.0, 10.0 or 100.0 μg of SEQ ID NO: 2 or SEQ ID NO: 3. Cells were counted after 24, 48 and 72 hours of incubation using light microscopy and trypan blue dye.
Table 7 Number of K562 cells (x 105) after treatment with SEQ ID NO: 2 or SEQ ID NO: 3
K562 cells in a dose-dependent manner. The trypan blue exclusion assay demonstrated that treatment of K562 cells with SEQ ID NO: 2 or SEQ ID NO: 3 was not cytotoxic since no trypan blue dye was incorporated by K562 cells.
Example 10 Differentiation of human committed erythroid precursor by SEQ ID NO: 2
Glycophorin A is the major glycoprotein of the human erythrocyte membrane. Maturation of committed human erythroid precursors is characterized by the expression of glycophorin A at the cell surface and by an increase in intracellular granulosity (Daniel and Greens, Vox Sang. S2:149, 2000; Wheater et al., Functional Histology, a text and color atlas, 2nd edition, Churchill Livingstone, U.K., 1987). Human committed erythroid precursors defined by the cell surface glycoprotein CD36 were isolated from expanded human cord blood CD34+ progenitors by positive immuno selection of CD36+ cells (Clonetics, San Diego, CA, USA). Human committed erythroid cells were seeded in 1.0 ml at 1.5 X 10*5 cells/ml in 6-well flat-bottomed tissue culture plates for 96 hours with 100.0 μg of SEQ ID NO: 2 or SEQ ID NO: 3. The expression of glycophorin A at the cell surface and the intracellular granulosity were monitored by flow cytometry. After 48 and 96 hours of incubation, human committed erythroid cells were washed twice by centrifugation with PBS and labeled with PE-conjugated glycophorin A monoclonal antibody (Caltag Laboratories, Burlingame, CA, USA) for 30 min at 4°C. After washing twice with PBS-1% bovine serum albumin, cellular fluorescence was determined. The intracellular granulosity was determined by the measure of side light scatter (SSC) using a flow cytometer. Flow cytometry was carried out on a FACSCalibur (Becton Dickinson) and analyzed using the program CELLQuest (Becton Dickinson). The percentages of cells in SSChl glycophorin A+ and in SSC10 glycophorin A+ were determined. SSChl is defined as > 450 units; SSC10 is defined as < 450 units.
Table 8 Percentages of human committed erythroid precursor cells in SSC -ihmi glycophorin
A+ and in SSC!o glycophorin A+ after treatment with SEQ ID NO: 2 or SEQ ID NO: 3
As shown in Table 8, SEQ ID NO: 2 induced the differentiation of human committed erythroid precursor cells in SSChl glycophorin A+ and in SSC10 glycophorin A cells.
Example 11 Effect of SEQ ID NO: 2 on human disseminated chronic myeloid leukemia K562 cells in severe combined immunodeficiency mice
Forty female severe combined immunodeficiency mice (SCID mice) were exposed to 1.8 Gy of radiation (rate: 7.5 Gy/h) from a γ source. Twenty-four hours after whole body inadiation (day 0), the 40 female SCID mice were weighed and randomized to form 4 groups (10 mice/group). The mean body weight of each group was not statistically different from the others (analysis of variance). Mice were injected intraperitoneally (ip) with 2.0 x 107 K562 cells in 0.5 ml of RPMI-1640 medium. SEQ ID NO: 2 (5'GGGTGG3') resuspended in 0.9% sodium chloride USP was administrated ip at 0.01, 0.1 and 1 mg per mouse per day from day 1 to day 29 (30 days). A vehicle group was ip injected with vehicle (0.9% sodium chloride USP) following the same schedule. The treatment schedule is summarized in the table below:
Table 9
The experiment was stopped at 120 days when mice were sacrificed. Survival was recorded two times per week.
The test evaluation expressed as a percentage (T/C%) and as the increased life span value (ILS%) of the control evaluation was determined. These are measures of the effectiveness of the compounds tested. Survival systems indicate a degree of success when T/C percentages exceed 125 and ILS percentages exceed 25. T is the median survival times of animals treated with drugs and C is the median survival time of control animals. T/C% and ILS% is expressed as following:
ILS% = [(T-C)/C] x 100 T/C% = [T/C] x 100
Statistical analysis was perfonned using StatView® (Abacus Concept, Berkeley, USA). Statistical analysis of the efficiency of the treatment was performed using the Bonfenoni/Durm test (ANOVA comparison).
Table 10
Survival time of SCID mice having human disseminated chronic myeloid K562 leukemia treated with SEQ ID NO: 2
As shown in Table 10, SEQ ID NO:2, at 0.01 mg/ ouse/day, significantly increased the life span of SOD mice having human disseminated chronic myeloid K562 leulcemia (ρ<0.05). After 120 days, 4 of 11 mice treated with SEQ ID NO:2 at 0.01 mg/mouse/day were alive while none of the 11 untreated mice was alive.
Example 12 Effect of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3 and SEQ ID NO: 4 on differentiation of bone marrow-derived cells from mice
The C57BL/6 mice are divided into 5 groups of 10 mice. Mice receive gamma- irradiation to induce a reduction in the number of bone marrow derived-cells and bone marrow precursor cells. On day 0, group 1 mice receive saline, group 2 receive SEQ ID NO: 1, group 3 receive SEQ ID NO: 2, group 4 receive SEQ ID NO: 3, group 5 receive SEQ ID NO: 4. Sequences resuspended in 0.9% sodium chloride USP are administrated ip at 0.01 mg per mouse per day for 7 days. After 7 days of treatment, the mice are sacrificed. Cells present in peripheral blood and in bone manow are counted and their phenotype determined by flow cytometry. Hemoglobin levels are also determined. Mice in groups 2, 3, 4 and 5 have more bone marrow-derived cells than the mice in group 1. Mice in groups 2, 3, 4 and 5 have more mature bone manow-derived cells than the mice in group 1. The levels of hemoglobin are more elevated in mice in groups 2, 3, 4 than in mice in group 1.
Example 13 Effect of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3 and SEQ ID NO: 4 on CML in SCID mice K562 cells (2 x 107 cells) are inoculated into SOD mice (severe combined immunodeficiency mice) as previously described (Beran et al., Hematol. Pathol. 8:135, 1994). The mice are divided into 5 groups of 10 mice. On day 0, group 1 mice receive saline, group 2 mice receive SEQ ID NO: 1, group 3 mice receive SEQ ID NO: 2, group 4 receive SEQ ID NO: 3, group 5 mice receive SEQ ID NO: 4. Sequences resuspended in 0.9% sodium chloride USP are administrated ip at 0.01 mg per mouse per day for 30 days.
After 30 days, the mice are sacrificed. Leukemic dissemination, leukemic cell phenotype and hemoglobin levels are analyzed. Mice in Group 1 have the most leukemia cells and dissemination. Mice in groups 2, 3, 4 and 5 have less leukemia cells and dissemination. Mice in groups 2, 3, 4 and 5 show a higher number of differentiated K562 cells than mice in group 1. Mice in groups 2, 3, 4 and 5 show more hemoglobin synthesis than the mice in group 1.
All patents, publications and abstracts cited above are incorporated herein by reference in their entirety. It should be understood that the foregoing relates only to preferred embodiments of the present invention and that numerous modifications or alterations may be made therein without departing from the spirit and the scope of the present invention as defined in the following claims.
Claims (17)
1. A composition comprising a 3'-OH, 5'-OH, chemically unmodified, synthetic phosphodiester nucleotide sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3 and SEQ ID NO: 4, and a pharmaceutically acceptable carrier, wherein the composition is effective to induce differentiation of cells or increase differentiation of pluripotent cells.
2. The composition of Claim 1, wherein the induction of differentiation of cells is induction of differentiation of leukemia cells.
3. A method comprising administration of an amount of a composition comprising a 3'-OH, 5 -OH, chemically unmodified, synthetic phosphodiester nucleotide sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, and SEQ ID NO: 4, and a pharmaceutically acceptable carrier, to an animal or a human having a disease associated with insufficient differentiation of cells, wherein the amount is effective to induce differentiation of the cells in the animal or the human.
4. The method of Claim 3, wherein the disease is leukemia, lymphoma, a non-malignant blood disorder, hemoglobinopathy, sickle cell disease, myelodysplastic syndrome, pancytopenia, anemia, thrombocytopenia or leukopenia.
5. The method of Claim 3, wherein the disease is leukemia.
6. The method of Claim 3, wherein induction of differentiation is induction of erythrocyte-like phenotype, monocyte-like phenotype, megakaryocyte-like phenotype, inhibition of proliferation or induction of hemoglobin synthesis in cells.
7. A method comprising administration of an amount of a composition comprising a 3'-OH, 5'-OH, chemically unmodified, synthetic phosphodiester nucleotide sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3 and SEQ ID NO: 4, and a pharmaceutically acceptable carrier, to an animal or a human, wherein the amount is effective to increase differentiation of pluripotent cells in the animal or the human.
8. The method of Claim 7, wherein the pluripotent cells are derived from bone marrow.
9. The method of Claim 7, wherein the animal or the human has received chemotherapy or radiotherapy.
10. The method of Claim 3, further comprising administration of a therapeutic agent.
11. The method of Claim 10, wherein the therapeutic agent is a chemotherapeutic drug, an immunosuppressive agent, a differentiating agent, an immunotherapeutic agent, an antimicrobial agent, an antiviral agent, a combination thereof, or radiotherapy.
12. Use of a 3'-OH, 5'-OH, chemically unmodified, synthetic phosphodiester nucleotide sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, and SEQ ID NO: 4, in the preparation of a medicament, wherein the medicament induces differentiation of cells or increases differentiation of pluripotent cells when administered to an animal or a human.
13. The use of Claim 12, wherein the medicament is useful for treating diseases associated with insufficient differentiation of cells.
14. The use of Claim 13, wherein the disease is leukemia.
15. The use of Claim 12, wherein the medicament induces terminal differentiation of leulcemic cells when administered to an animal or a human with leulcemia
16. The use of Claim 13, wherein the disease is leukemia, lymphoma, a non-malignant blood disorder, hemoglobinopathy, sickle cell disease, myelodysplastic syndrome, pancytopenia, anemia, tlirombocytopenia or leukopenia.
17. The use of Claim 12, wherein the pluripotent cells are derived from bone marrow, liver, spleen, lymph nodes, thymus or cord blood.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US28615801P | 2001-04-24 | 2001-04-24 | |
| US60/286,158 | 2001-04-24 | ||
| US10/127,645 US7087586B2 (en) | 2001-04-24 | 2002-04-22 | Oligonucleotide compositions and their use to induce differentiation of cells |
| US10/127,645 | 2002-04-22 | ||
| PCT/CA2002/000573 WO2002085340A2 (en) | 2001-04-24 | 2002-04-23 | Oligonucleotide compositions and their use to induce differentiation of cells |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2002252891A1 true AU2002252891A1 (en) | 2003-04-17 |
| AU2002252891B2 AU2002252891B2 (en) | 2007-09-20 |
Family
ID=26825829
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2002252891A Ceased AU2002252891B2 (en) | 2001-04-24 | 2002-04-23 | Oligonucleotide compositions and their use to induce differentiation of cells |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US7087586B2 (en) |
| EP (1) | EP1381375B1 (en) |
| JP (1) | JP4460220B2 (en) |
| KR (1) | KR100913860B1 (en) |
| AT (1) | ATE489467T1 (en) |
| AU (1) | AU2002252891B2 (en) |
| CA (1) | CA2445071A1 (en) |
| DE (1) | DE60238393D1 (en) |
| IL (2) | IL158534A0 (en) |
| MX (1) | MXPA03009761A (en) |
| NZ (1) | NZ529160A (en) |
| WO (1) | WO2002085340A2 (en) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2002341264B2 (en) * | 2001-10-03 | 2007-07-12 | Bioniche Life Sciences Inc. | Therapeutically useful triethyleneglycol cholesteryl oligonucleotides |
| CN101160399A (en) * | 2002-04-22 | 2008-04-09 | 拜奥尼茨生命科学公司 | Oligonucleotide compositions and their use for the modulation of immune responses |
| US20050101576A1 (en) * | 2003-11-06 | 2005-05-12 | Novacea, Inc. | Methods of using vitamin D compounds in the treatment of myelodysplastic syndromes |
| WO2007028985A2 (en) * | 2005-09-07 | 2007-03-15 | The Secretary Of State For Defence | Adjuvanted vaccine |
| US8222225B2 (en) * | 2008-05-21 | 2012-07-17 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Method of treating pneumoconiosis with oligodeoxynucleotides |
| US8053422B2 (en) * | 2008-12-04 | 2011-11-08 | The United States Of America As Represented By The Department Of Health And Human Services | Anti-cancer oligodeoxynucleotides |
| GB0906234D0 (en) | 2009-04-14 | 2009-05-20 | Secr Defence | Vaccine |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5567604A (en) * | 1993-04-23 | 1996-10-22 | Aronex Pharmaceuticals, Inc. | Anti-viral guanosine-rich oligonucleotides |
| US5866332A (en) * | 1994-02-02 | 1999-02-02 | Incyte Pharmaceuticals, Inc. | Human myeloid terminal differentiation response gene |
| US5994320A (en) * | 1995-02-06 | 1999-11-30 | Regents Of The University Of Minnesota | Antisense oligonucleotides and methods for treating central nervous system tumors |
| US5851984A (en) * | 1996-08-16 | 1998-12-22 | Genentech, Inc. | Method of enhancing proliferation or differentiation of hematopoietic stem cells using Wnt polypeptides |
| NZ508650A (en) * | 1998-05-14 | 2003-05-30 | Coley Pharm Gmbh | Regulating hematopoiesis using unmethylated C and G CpG-oligonucleotides with a phosphorothioate modification |
| ES2288883T3 (en) * | 1999-12-13 | 2008-02-01 | Bioniche Life Sciences Inc. | THERAPEUTICALLY USEFUL SYNTHETIC OLIGONUCLEOTIDES. |
| WO2002018593A2 (en) * | 2000-08-29 | 2002-03-07 | Bioniche Life Sciences Inc. | Modulation of fas and fasl expression |
| US20020091095A1 (en) * | 1999-12-13 | 2002-07-11 | Phillips Nigel C. | Modulation of Fas and FasL expression |
| JP4215429B2 (en) | 1999-12-28 | 2009-01-28 | バイオニケ ライフ サイエンシーズ インコーポレイテッド | Hyaluronic acid in cancer treatment |
| DE60231986D1 (en) * | 2001-08-17 | 2009-05-28 | Bioniche Life Sciences Inc | OLIGONUCLEOTIDE COMPOSITIONS AND THEIR USE FOR THE INDUCTION OF APOPTOSIS |
-
2002
- 2002-04-22 US US10/127,645 patent/US7087586B2/en not_active Expired - Fee Related
- 2002-04-23 JP JP2002582914A patent/JP4460220B2/en not_active Expired - Fee Related
- 2002-04-23 NZ NZ529160A patent/NZ529160A/en not_active IP Right Cessation
- 2002-04-23 MX MXPA03009761A patent/MXPA03009761A/en active IP Right Grant
- 2002-04-23 EP EP02721915A patent/EP1381375B1/en not_active Expired - Lifetime
- 2002-04-23 IL IL15853402A patent/IL158534A0/en unknown
- 2002-04-23 WO PCT/CA2002/000573 patent/WO2002085340A2/en active Application Filing
- 2002-04-23 AU AU2002252891A patent/AU2002252891B2/en not_active Ceased
- 2002-04-23 CA CA002445071A patent/CA2445071A1/en not_active Abandoned
- 2002-04-23 KR KR1020037013799A patent/KR100913860B1/en not_active IP Right Cessation
- 2002-04-23 DE DE60238393T patent/DE60238393D1/en not_active Expired - Lifetime
- 2002-04-23 AT AT02721915T patent/ATE489467T1/en not_active IP Right Cessation
-
2003
- 2003-10-21 IL IL158534A patent/IL158534A/en not_active IP Right Cessation
-
2006
- 2006-06-08 US US11/449,152 patent/US20070010472A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Nishikawa et al. | Biodegradable CpG DNA hydrogels for sustained delivery of doxorubicin and immunostimulatory signals in tumor-bearing mice | |
| KR101092043B1 (en) | Oligonucleotide compositions and their use for the modulation of immune responses | |
| US20070010472A1 (en) | Oligonucleotide compositions and their use to induce differentiation of cells | |
| US7893242B2 (en) | Oligonucleotide compositions and their use to induce apoptosis | |
| US7662792B2 (en) | Modulation of Fas and FasL expression | |
| AU2002252891A1 (en) | Oligonucleotide compositions and their use to induce differentiation of cells | |
| AU2002330663A1 (en) | Oligonucleotide compositions and their use to induce apoptosis | |
| JPH07501525A (en) | Treatment of melanoma with antisense oligonucleotides against the c-myb proto-oncogene | |
| ES2353885T3 (en) | OLIGONUCLEOTID COMPOSITIONS AND THEIR USE TO INDUIT THE DIFFERENTIATION OF CELLS. | |
| CN102703447B (en) | Oligonucleotide with breast cancer treatment effect | |
| EP1313853B1 (en) | Modulation of fas and fasl expression by a synthetic phosphodiester oligonucleotide and an anti-fas antibody | |
| JP2004528851A6 (en) | Antisense oligonucleotide for epidermal growth factor receptor | |
| ES2383671T3 (en) | Modulation of Fas and FasL expression by a synthetic oligonucleotide phosphodiester and an anti-Fas antibody | |
| JP2002507186A (en) | Antisense oligonucleotides to c-kit proto-oncogene and uses thereof | |
| AU2001268863B2 (en) | Modulation of FAS and FASL expression | |
| AU2001268863A2 (en) | Modulation of FAS and FASL expression | |
| AU2001268863A1 (en) | Modulation of FAS and FASL expression |